8-K: Orgenesis Inc. Executes Debt-for-Equity Swap, Reducing Liabilities by $16 Million

Orgenesis Inc. has entered into agreements to exchange approximately $16 million in debt for over 15.7 million shares of common stock with three debt holders.

Summary

• Orgenesis Inc. has entered into debt exchange agreements with three convertible debt holders.
• A total of $16,007,372 of outstanding principal and accrued interest will be exchanged for 15,776,947 shares of common stock.
• $14,860,422 of debt will be exchanged at $1.03 per share, and $1,146,950 will be exchanged at $0.85 per share.
• These exchange prices represent premiums of 102% and 67%, respectively, compared to the closing price on May 21, 2024.
• Yehuda Nir will exchange $13,176,000 for 12,955,611 shares, subject to a beneficial ownership limitation of 19.99% of outstanding shares.
• Aharon Lukach will exchange $1,458,171 for 1,488,132 shares.
• Yosef Dotan will exchange $1,373,201 for 1,333,204 shares.
• The shares are being issued under exemptions from registration requirements.
• The debt exchange agreements were all dated May 21, 2024.

Sentiment

Score: 7

Explanation: The debt exchange is a positive step for the company's financial health, but the dilution of shares is a concern. The high premiums suggest confidence from debt holders.

Positives

• The debt exchange reduces the company's outstanding debt by over $16 million.
• The exchange prices represent a premium over the market price, indicating a positive valuation by the debt holders.
• The agreements simplify the company's capital structure by converting debt to equity.
• The beneficial ownership limitation protects against excessive dilution from the Yehuda Nir exchange.

Negatives

• The debt exchange will result in the issuance of over 15.7 million new shares, which could dilute existing shareholders.
• The beneficial ownership limitation for Yehuda Nir could create uncertainty about the final number of shares issued to him.

Risks

• The issuance of a large number of new shares could put downward pressure on the stock price.
• The beneficial ownership limitation for Yehuda Nir may require future shareholder approval or a waiver from Nasdaq.
• The company's ability to issue the full amount of shares to Yehuda Nir is dependent on the company's share price and outstanding share count.

Future Outlook

The company will determine at the end of each fiscal quarter if any shares held in abeyance for Yehuda Nir can be issued without exceeding the beneficial ownership limitation.

Industry Context

Debt-for-equity swaps are a common strategy for companies looking to reduce their debt burden and improve their balance sheet, particularly in the biotech sector where companies often rely on debt financing.

Comparison to Industry Standards

• Debt-for-equity swaps are a common practice in the biotech industry, especially for companies with significant debt loads.
• Comparable companies in the biotech sector, such as those in early-stage development, often use similar strategies to manage their capital structure.
• The premiums offered in this exchange, 102% and 67%, are relatively high, suggesting the debt holders see value in the company's future prospects.
• The beneficial ownership limitation is a standard clause to prevent any single shareholder from gaining excessive control.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Debt holders will become shareholders, aligning their interests with the company's success.
• The company's financial position will improve due to the reduction in debt.

Next Steps

• The company will issue the shares to the debt holders.
• The company will monitor the beneficial ownership limitation for Yehuda Nir and issue additional shares as permitted.
• The company will make required regulatory filings.

Key Dates

Keywords

debt exchange, equity, convertible debt, shares, dilution, beneficial ownership, Nasdaq, Orgenesis Inc.